Friday, July 24, 2026 – 8:30 am – 4:15 pm
Masur Auditorium – Building 10 NIH Bethesda Campus
Chairs/Organizers
Lorenzo Leggio, M.D., Ph.D., NIDA/NIAAA Mike Krashes, Ph.D., NIDDK
Schedule
8:45 – 8:55 Lorenzo Leggio, M.D., Ph.D. (NIDA/NIAAA) and Mike Krashes, Ph.D. (NIDDK)
Welcome
8:55 – 9:00 Janice Lee, D.D.S., M.D., M.S., Deputy Director for Intramural Clinical Research, NIH
Opening Remarks
9:00 – 10:20 Session 1: Glucose Homeostasis Moderator: Marc Reitman, M.D., Ph.D. (NIDDK)
9:00 – 9:20 Josephine Egan, M.D. (NIA)
NIA’s extended role in development of GLP-1 receptor agonists for treating diabetes and obesity
9:20 – 9:40 Stephanie Chung, M.B.B.S. (NIDDK)
Incretin analogues in youth-onset type 2 diabetes: challenges and opportunities
9:40 – 10:00 Arthur Sherman, Ph.D. (NIDDK)
Comparing tirzepatide and semaglutide: Insights from longitudinal mathematical modeling
10:00 – 10:20 Jeremy Weiss, M.D., Ph.D. (NLM)
Characterization of GLP-1 user trajectories in the PubMed Open Access corpus
10:20 – 10:25 Break
10:25 – 12:05 Session 2: Adipose Tissue, Ectopic Adiposity, and Weight Control Moderator: Chris Koh, M.D., M.H.Sc. (NIDDK)
10:25 – 10:45 Andrew Lutas, Ph.D. (NIDDK)
Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1Rexpressing hindbrain neurons
10:45 – 11:05 Adrienne Guarnieri, Ph.D. (NIDDK)
GIPR-dependent action of anti-obesity medications in human white and brown adipocytes
11:05 – 11:25 Marissa Lightbourne, M.D., M.P.H. (NIDDK)
GLP-1RA efficacy and safety in patients with lipodystrophy: a model of severe metabolic syndrome without obesity
11:25 – 11:45 Yaron Rotman, M.D., M.Sc. (NIDDK)
Using GLP-1RA to treat MASLD
11:45 – 12:45 Session 3: Neurodegeneration Moderator: Mike Krashes, Ph.D. (NIDDK)
11:45 – 12:05 Nigel Greig, Ph.D. (NIA)
GLP-1-based drugs and neurodegenerative disorders
12:05 – 12:25 Apostolos Manolopoulos, M.D., M.Sc. (NIA)
Efficacy of GLP-1 receptor agonists on neurological disorders: results of a systematic review and meta-analysis
12:25 – 12:45 Caio Henrique Yokoyama Mazucanti, Ph.D. (NIA)
A New ‘vector’ for brain-only GLP-1R agonism: A proof-of-concept proposal
12:45 – 12:50 Interim Remarks: George Koob, Ph.D., Director, NIAAA
12:50 – 1:20 Lunch
1:20 – 2:20 Session 4: Addictive Behaviors Moderator: Amy Newman, Ph.D. (NIDA)
1:20 – 1:40 Leandro F. Vendruscolo, Pharm.D., M.Sc., Ph.D. (NIDA/NIAAA)
GLP-1 and opioid addiction: is there a link?
1:40 – 2:00 Lorenzo Leggio, M.D., Ph.D. (NIDA/NIAAA)
Repurposing GLP-1 therapies for alcohol use disorder
2:00 – 2:20 Stephanie Weiss, M.D., Ph.D. (NIDA)
Weighs and miens: clinical observations from an ongoing alcohol semaglutide trial
2:20 – 2:25 Break
2:25 – 4:05 Session 5: New Developments in Translational Research Moderator: Rebecca Brown, M.D., M.H.Sc. (NIDDK)
2:25 – 2:45 Melissa Wilson, Ph.D. (NHGRI)
The evolutionary origin of exendin4, the original GLP-1RA
2:45 – 3:05 Alison Motsinger-Reif, Ph.D. (NIEHS)
Pharmacogenomics of GLP-1s
3:05 – 3:25 Flavia Barbano, Ph.D. (NIDA)
Mapping the GLP1R neuronal connectome
3:25 – 3:45 Ross Cheloha, Ph.D. (NIDDK)
Modifying glucagon family receptor signaling via through antibody-mediated ligand delivery
3:45 – 4:05 Peter Choyke, M.D., F.A.C.R. (NCI)
68Ga-DOTA-Exendin-4 targeting GLP1-Receptor for PET imaging of Insulinoma
4:05 – 4:10 Gregory Germino, M.D., Deputy Director, NIDDK
Closing Remarks
4:10 – 4:15 Nora Volkow, M.D., Director, NIDA
Closing Remarks
